Non-Hodgkin’s Lymphoma
(click to enlarge)
"The first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin’s lymphoma (NHL), shows that many cases of the disease are driven by alterations in the JAK/STAT3 cell signaling pathway. The study also demonstrates, in mice implanted with human-derived ALCL tumors, that the disease can be inhibited by compounds that target this pathway, raising hopes that more effective treatments might soon be developed."
---CUMC Newsroom
“Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma.”
AUTHORS: Ramona Crescenzo*, Francesco Abate*, Elena Lasorsa*, et al
LINK TO PUBLICATION:
Cancer Cell 2015 April 13; doi:10.1016/j.ccell.2015.03.006.
* These authors have contributed equally to this work.